To hear about similar clinical trials, please enter your email below
Trial Title:
Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions
NCT ID:
NCT05907551
Condition:
Neoplasms
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
Questionnaires
Description:
25-items questionnaire
Arm group label:
Patients with Breast Cancer
Arm group label:
Patients with Digestive System Cancer
Arm group label:
Patients with Gynecologic Cancer
Arm group label:
Patients with Head and Neck Cancer
Arm group label:
Patients with Lung Cancer
Arm group label:
Patients with Nervous System Tumors
Arm group label:
Patients with Urological Cancer
Summary:
Cancer treatments can trigger cutaneous side-effects, as well as nail and hair
toxicities. When related to drug treatment, this iatrogeny depends on the type of drug,
its dosage and individual susceptibility. Although these dermatological adverse events
are rarely serious, they can significantly alter patients' quality of life, and may even
necessitate the introduction of curative treatment.
The impact of these side effects can be mitigated by the use of dermo-cosmetic products
and aesthetic solutions. However, most of this supportive care is not reimbursed by the
health insurance system, representing a source of inequalities in access to healthcare
for cancer patients.
Detailed description:
This study aims at establishing, in a cohort of patients with solid tumors, the state of
their knowledges, given information and their financial capacities regarding access to
dermo-cosmetics and aesthetic solutions, that are used in the attenuation of cancer
treatments' side-effects.
Criteria for eligibility:
Study pop:
This study will enroll patients with solid tumors in 7 different cohorts according to
tumor location (30 patients per location)
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Age > 18 years
- Patients with solid tumors (eligible localization include: digestive system, Head
and Neck, Breast, Brain, Lung Tumors, Urological and Gynecologic cancers)
- Patients able to read and understand French
- Patients that has expressed their consent and with signed consent form
Exclusion Criteria:
- Minor or patients placed under guardianship or supervision
- Patients unable to read French
- Patients placed under judicial protection
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
Institut de cancérologie Strasbourg Europe
Address:
City:
Strasbourg
Zip:
67033
Country:
France
Status:
Recruiting
Contact:
Last name:
Nelly ETIENNE-SELLOUM, PharmD
Start date:
July 25, 2023
Completion date:
October 25, 2023
Lead sponsor:
Agency:
Institut de cancérologie Strasbourg Europe
Agency class:
Other
Source:
Institut de cancérologie Strasbourg Europe
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05907551
